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It has been recognized that systemic inflammatory markers (SIMs) are associated with patient survival 
in various types of cancer. This study aimed to determine the optimal cut-off values, and to evaluate 
the prognostic performance of SIMs for oral squamous cell carcinoma (OSCC) within the framework 
of the American Joint Committee of Cancer (AJCC) cancer staging manual, 8th edition. Records were 
collected for a total 291 patients who had had a peripheral blood test within 1 week prior to surgery 
and had undergone the surgical resection of OSCC in a single institution between 2005 and 2018. The 
cut-off values of SIMs were obtained, and the survival analyses for overall survival (OS) and disease-
free survival (DFS) were performed. Multivariate analyses incorporating other clinicopathologic factors 
were performed to verify the independent risk factors for survival. The cut-off values of neutrophil-
to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were 2.23, 135.14 for OS and 2.16, 
131.07 for DFS, respectively, demonstrating a significant association for OS and DFS in OSCC. AJCC 
pathologic regional lymph node category (pN) (P < 0.001), perineural invasion (PNI) (P < 0.001) and 
NLR (P < 0.001) were independent predictors for OS. Meanwhile, for DFS, AJCC pN (P = 0.018) and NLR 
(P = 0.015) were shown to be independent predictors. Before the curative surgery, NLR and PLR could 
be auxiliary parameters for OS and DFS in OSCC. And based on the 8th edition of AJCC staging system, 
elevated NLR will be a potential indicator of the worse OS or DFS along with pN or PNI in OSCC.
The ‘primary tumor, regional lymph node and distant metastasis’ (TNM) staging system has been generally 
accepted as a worldwide classification tool for management of oral squamous cell carcinoma (OSCC)1–4. The 
product of constant revisions to improve the prognostic stratification, the 8th edition of the American Joint 
Committee of Cancer (AJCC) cancer staging manual was recently  published4. However, this staging framework 
has focused on the clinical and pathological characteristics of tumor rather than host factors and most of the 
pathological data can be identified  postoperatively5. Accordingly, any prognostic factor that can be obtained 
before surgery might be valuable in establishing a treatment plan for OSCC.
Among host factors in cancer initiation and progression which have been investigated, inflammatory condi-
tion is known as one of the  hallmarks3,6. Research on interactions between tumor development and systemic 
inflammation indicates that chronic inflammation can stimulate carcinogenesis, the degree of systemic inflam-
mation correlating with oncologic  outcomes7–9. Peripheral blood sampling is a simple and useful modality for 
measuring the systemic inflammation of patients in clinical  situations10,11. Based on the peripheral blood dif-
ferential counts, several combined indices have been suggested as prognostic markers. Systemic inflammatory 
markers (SIMs) including neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), plate-
let-to-lymphocyte ratio (PLR) and albumin are significantly associated with the survival of OSCC  patients12–15. 
However, there are discrepancies in the prognostic impact and cut-off values among those SIMs for OSCC.
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The aim of the present study was to verify the prognostic significance of preoperative SIMs, including NLR, 
LMR, PLR and albumin for the management of OSCC, within the framework of the AJCC cancer staging manual, 
8th edition, as well as to determine the optimal cut-off value of SIMs for OSCC patients who are undergoing 
definitive surgery.
Material and methods
patient demographics and clinical data. This study retrospectively enrolled adult patients (18 years or 
older) who had been newly diagnosed with OSCC and undergone curative surgery without neoadjuvant therapy 
at Yonsei University Dental Hospital from November 1, 2005, through August 31, 2018. Only patients who had 
had a peripheral blood test within 1 week prior to surgery were included in the study. Exclusion criteria included 
the following conditions: patients who had other concomitant primary cancer, distant metastatic cancer, perio-
perative mortality, a history of previous head and neck cancer, previous radiotherapy and/or chemotherapy, 
hematological disorders, infection, inflammatory conditions, autoimmune disease, administration of steroids 
or for whom preoperative laboratory data within 1 week before surgery was lacking. Initially, 496 patients were 
identified. After excluding 205 patients for insufficient data or meeting the exclusion criteria, a total of 291 
patients were evaluated. Demographic, laboratory, and clinical data were analyzed. Information was collected 
on any comorbidity at the time of OSCC diagnosis and the Charlson comorbidity index (CCI) was calculated. 
A high comorbidity score was defined as a CCI of ≥ 3. Disease staging was based on the 8 h edition of the AJCC 
cancer staging manual (2018). LMR was calculated by dividing the absolute lymphocyte count by the absolute 
monocyte count. NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte 
count. PLR was calculated by dividing the absolute platelet count by the absolute lymphocyte count.
The Ethics Review Board of Yonsei University Dental Hospital Institutional Review Board approved the 
study (IRB No. 2-2018-0047) and accepted that informed consent was not required as the study had a non-
interventional retrospective design and all data were analyzed anonymously. All procedures of the study involv-
ing human participants were in accordance with the Declaration of Helsinki (1964) and its later amendments 
or comparable ethical standards. All authors had access to the study data and reviewed and approved this study.
Statistical analysis. A receiver operating characteristic (ROC) curve analysis was done in order to obtain 
the cut-off values of LMR, NLR, PLR and albumin for overall survival (OS) and disease-free survival (DFS). The 
values with maximal sensitivity and specificity were selected for analysis. OS was calculated from the date of 
surgery to death from any cause. DFS was calculated from the date of surgery to the date of recurrence, or death 
from any cause. The Kaplan–Meier curve was used to analyze patients’ survival and the survival outcomes were 
assessed with a log-rank test. If the patient survived without an event, survival was censored at the latest date of 
follow-up when no event was confirmed. Univariate and multivariate analyses were done to identify independ-
ent risk factors for survival using Cox proportional hazards regression models. All analyses were performed 
using IBM SPSS Statistics for Windows, version 23.0 (IBM Corp., Armonk, NY, USA). A P value of < 0.05 was 
considered to be statistically significant.
Results
Baseline characteristics. The demographic and clinicopathological characteristics of 291 patients are 
presented in Table 1. The mean follow-up period for surviving patients was 41 months (range 3–144 months). 
There were 183 men and 108 women, median age at diagnosis being 63 years (range 24–91). The most com-
mon primary site was mandibular gingiva, followed by tongue and buccal cheek mucosa. Patients were divided 
according to the 8th edition of the AJCC TNM staging manual: stage I (n = 67, 23.0%); stage II, (n = 63, 21.6%) 
stage III (n = 35, 12.0%); stage IVA (n = 89, 30.6%); stage IVB (n = 37, 12.7%). A ma jority of the enrolled patients 
had clinically N0 disease (207/291, 71.1%), and a relatively better histologic grade ranging from moderately to 
well-differentiated disease (199/291, 68.4%). Less than half of the patients received adjuvant treatment after the 
surgery (120/291, 41.2%) and approximately three-quarters of the patients survived (50/291, 17.2%).
Cut-off values of SIMs. Differential white blood cell count, calculated ratios and albumin are shown in 
Table 2. The mean NLR, LMR, PLR and albumin were 2.61, 5.01, 141.26 and 4.34 and the medians were 2.04 
(range (0.50–32.36), 4.58 (0.67–14.63), 127.27 (45.95–655.56) and 4.40 (2.40–5.60), respectively. According to 
the ROC curve analysis, the cut-off values of SIMs were separately determined for OS and DFS. The cut-off val-
ues of NLR, LMR, PLR and albumin were 2.23, 4.65, 135.14 and 4.35 for OS and 2.16, 4.45, 131.07 and 4.35 for 
DFS, respectively ***(Supplementary Tables S1, S2; Figures S1, S2).
Survival analysis according to the SIMs. The OSCC patients were divided into two groups according 
to the cut-off values for Kaplan–Meier analysis. NLR showed statistically significant association with both OS 
and DFS (P = 0.001 and P < 0.001). PLR also showed statistically significant association with both OS and DFS in 
OSCC patients (P = 0.037 and P = 0.016). A trend towards better survival was observed for patients with higher 
LMR and albumin, but the results lacked statistical significance for both OS and DFS (P = 0.572, 0.307 and P = 0. 
130, 0.484) (Figs. 1, 2).
cox proportional hazards regression model. The Cox proportional hazards regression model revealed 
that AJCC pathologic regional lymph node category (pN) [converted into a binomial variable of N2, 3 vs. 0, 1; 
hazard ratio (HR) 2.29, 95% confidence interval (CI) 1.27–4.10, P < 0.001], perineural invasion (PNI) (HR 2.29, 
95% CI 1.27–4.10, P < 0.001) and NLR (≥ 2.23 vs. < 2.23; HR 2.29, 95% CI 1.27–4.10, P < 0.001) were independent 
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predictors for OS (Table 3). For DFS, AJCC pN (N2, 3 vs. 0, 1; HR 1.70, 95% CI 1.10–2.65, P = 0.018) and NLR 
(≥ 2.16 vs. < 2.16; HR 1.82, 95% CI 1.12–2.94, P = 0.015) were shown to be independent predictors (Table 4).
Discussion
In the present study, we investigated SIMs as prognostic factors that can simply be analyzed before surgery on 
OSCC. Based on the cut-off value and Kaplan–Meier survival analysis, we confirmed that elevated NLR and PLR 
are negative predictors for OS and DFS. Meanwhile, LMR or albumin did not present any significant correlation 
with survival. However, there is a discrepancy among the literature regarding the prognostic impact of SIMs. 
Several researchers have also documented that NLR is significantly associated with OS, DFS or disease specific 
survival (DSS) of OSCC  patients3,10,14,16,17. And a recent study proposed a systemic immune-inflammation index 
(SII) calculated by dividing a multiplication of the absolute neutrophil and platelet count by the absolute lym-
phocyte count. Diao et al. highlighted the results that a higher SII indicates a poor prognosis for OS and DFS in 
OSCC  patients18. Kao et al. presented a nomogram incorporating only NLR and albumin for OS prediction in 
OSCC  patients5. Ong et al. demonstrated that LMR and PLR, not NLR, were independent prognostic indicators 
for OS and DFS in early stage (pT1N0 or pT2N0) tongue  cancer7. In the study reported by Chen et al., PLR rather 
than NLR displayed significant associations with OS and DFS of OSCC  patients19. Further multicenter research 
with a large population remains to be performed for a worldwide consensus of SIMs.
We also performed multivariate analysis using the Cox proportional hazards regression model with the 
clinicopathologic parameters that were obtained after surgery, including the depth of invasion and extranodal 
extension (ENE) according to the AJCC cancer staging manual, 8th edition. pN and NLR were found to be inde-
pendent prognostic factors for both OS and DFS in OSCC patients and PNI was another significant indicator 
for OS. These factors are also mentioned in previous literature, but based on the 7th edition of the AJCC cancer 
staging  Manual16,20. A staging system proposed by Lee et al., composed of primary tumor category (pT), pN, 
PNI and NLR, demonstrated better prognostic discrimination compared to the 7th edition of the AJCC staging 
system for  OSCC16. Mattavelli et al. also analyzed clinicopathologic and inflammatory factors of which ENE, 
PNI and NLR were significant prognostic indicators for survival of OSCC  patients21. To the best of our knowl-
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Table 1.  Clinicopathologic characteristics of patients with oral squamous cell carcinoma. CCI Charlson 
comorbidity index, FOM floor of mouth, RMT retromolar trigone, AJCC American Joint Committee on 
Cancer, pT pathologic primary tumor categories, pN pathologic regional lymph node categories, NA not 
applicable, RTx radiotherapy, CTx chemotherapy, CCRT concurrent chemoradiotherapy.
Table 2.  Inflammatory markers, calculated ratios and cut-off values in patients with oral squamous cell 
carcinoma. OS overall survival, DFS disease-free survival, NA not applicable, NLR neutrophil–lymphocyte 
ratio, LMR lymphocyte-monocyte ratio, PLR platelet-lymphocyte ratio.
Parameter Mean ± SD Median (range)
Cut-off value
OS DFS
Differential white blood cell count
Neutrophil count,  109/L 4.38 ± 2.10 3.92 (1.52–17.15) NA NA
Lymphocyte count,  109/L 1.98 ± 0.67 1.90 (0.32–3.95) NA NA
Monocyte count,  109/L 0.43 ± 0.17 0.39 (0.10–1.08) NA NA
Platelet count,  109/L 248.04 ± 66.54 247.00 (48.0–634.0) NA NA
Calculated ratios
NLR 2.61 ± 2.52 2.04 (0.50–32.36) 2.23 2.16
LMR 5.01 ± 2.09 4.58 (0.67–14.63) 4.65 4.45
PLR 141.26 ± 72.24 127.27 (45.95–655.56) 135.14 131.07
Albumin 4.34 ± 0.37 4.40 (2.40–5.60) 4.35 4.35
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Manual. The result of the present study indicated that peripheral blood markers of host inflammation could be 
a supplementary indicator of survival in the current TNM staging system for OSCC.
NLR has been documented as a valuable predictor and its cut-off value has been examined in vari-
ous types of cancer: NLR ≥ 3.5 for esophageal squamous cell carcinoma (ESCC)22, ≥ 2.7 for intrahepatic 
 cholangiocarcinoma23, ≥ 2.5 for DFS in  melanoma24 and ≥ 2.36 for DFS and DSS in gastric  cancer25 were asso-
ciated with poorer survival outcome. With regard to OSCC, the cut-off values of NLR were reported to range 
from 1.9 to 2.95 for OS and from 1.9 to 2.95 for  DSS3,7,20,26–30. In the present study, the cut-off values of NLR as 
2.23 for OS and 2.16 for DFS. Additionally, PLR and its threshold have also been investigated in diverse cancer 
types: PLR ≥ 149 for pancreatic  cancer31, ≥ 138.35 for cervical  cancer32, ≥ 181.1 and 185.5 for breast  cancer33,34 
and ≥ 150 for  ESCC22 were associated with poorer survival outcome. As for OSCC, although there is limited 
insufficient data, the cut-off values of PLR ranged from 124.8 to 138.47 for  OS7,19,35–37. In this study, we found the 
cut-off values of PLR to be 135.14 for OS and 131.07 for DFS. Our findings were broadly consistent with those 
in previous publications. This might be because most of the cut-off values of NLR and PLR for OSCC patients 
have been predominantly derived from the Asian population; data on the Caucasian population are still lacking.
Recently, reference values of NLR and PLR in the healthy general population have been reported for the 
Republic of  Korea38. The mean of NLR and PLR among OSCC patients in this study was generally higher than 
those of reference mean values from the healthy population. This might be another clue of systemic inflammatory 
condition associated with carcinogenesis in OSCC patients. Although the mechanism of interaction between 
systemic inflammation and cancer has not been fully explained, theoretical backgrounds for cancer-related 
inflammation have gradually emerged. Neutrophils exhibit anti-tumor responses concurrently with pro-tumor 
activities in tumor microenvironment. Neutrophils limit tumor growth through direct, antibody-dependent 
cytotoxic effects and activation of immune cells. On the other hand, cancer cells induce the systemic activation 
of neutrophil extracellular matrix traps, which lead to increased adhesion, destruction of basement membrane, 
invasion of cancer cells and  metastasis39. The cytokines from neutrophil, including vascular endothelial growth 
factor, fibroblast growth factor 2, oncostatin M, matrix metalloproteinase  939–41 and  elastase42 are involved in 
Figure 1.  Kaplan–Meier curves for overall survival according to the preoperative systemic inflammatory 
markers: (A) neutrophil–lymphocyte ratio (P = 0.001); (B) lymphocyte–monocyte ratio (P = 0.572); (C) platelet–
lymphocyte ratio (P = 0.037); (D) Albumin (P = 0.307).
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Figure 2.  Kaplan–Meier curves for disease-free survival according to the preoperative systemic inflammatory 
markers: (A) neutrophil–lymphocyte ratio (P < 0.001); (B) lymphocyte–monocyte ratio (P = 0.130); (C) platelet–
lymphocyte ratio (P = 0.016); (D) Albumin (P = 0.484).
Table 3.  Cox proportional hazard regression model for overall survival. HR hazard ratio, CI confidence 
interval, CCI Charlson comorbidity index, AJCC American Joint Committee on Cancer, pT pathologic primary 
tumor categories, pN pathologic regional lymph node categories, NLR neutrophil–lymphocyte ratio, LMR 
lymphocyte-monocyte ratio, PLR platelet-lymphocyte ratio. * Statistically significant.
Parameter
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age (≥ 63) 1.31 (0.75–2.29) 0.341
Smoking history 0.85 (0.47–1.55) 0.601
Alcohol history 1.00 (0.57–1.76) 0.989
CCI (≥ 3 points) 0.58 (0.00–134.19) 0.453
AJCC pT (T3, T4a and T4b) 1.74 (0.10–3.05) 0.051
AJCC pN (N2, N3) 2.35 (1.34–4.11)  < 0.001* 2.29 (1.27–4.10) 0.006*
Perineural invasion 2.89 (1.47–5.66) 0.002* 2.17 (1.09–4.33) 0.028*
Lymphovascular permeation 1.78 (0.89–3.57) 0.102
Resection margin status (close or involved) 0.88 (0.49–1.58) 0.676
NLR (≥ 2.23) 2.01 (1.15–3.53) 0.015* 1.78 (1.01–3.14) 0.045*
LMR (< 4.65) 0.88 (0.50–1.53) 0.638
PLR (≥ 135.14) 1.67 (0.96–2.92) 0.071
Albumin (< 4.35) 1.31 (0.75–2.29) 0.340
7
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:12111  | https://doi.org/10.1038/s41598-020-68991-3
www.nature.com/scientificreports/
chronic inflammation and cancer progression. In addition, neutrophil has been found to be related with sup-
pression of cell-mediated immunity for cancer  surveillance43. Rao et al. reported that elastase from neutrophils 
can also inhibit recruitment of T lymphocyte into the inflammation  sites42. An investigation by Gabrilovich et al. 
revealed the T cell suppression mechanism whereby myeloid-derived suppressor cells overproduce the reactive 
oxygen species and arginase  144. Also, there have been several explanations for the association between plate-
lets and cancer progression. Platelets can interact with tumor cells and provide mechanical support on  them45. 
Sabrkhany et al. confirmed that platelets can also promote cancer cell proliferation and metastasis by increasing 
angiogenesis and vessel  permeability46. The study of Nieswandt et al. revealed that platelets also defend cancer 
cells from the host immune system by diminishing the cytotoxic activity of natural killer  cells47.
Meanwhile, elevated NLR and PLR also result from relative lymphopenia. Possible mechanisms for lym-
phopenia and inferior survival outcome in cancer patients have been suggested. The lymphocyte is known to 
be a critical component of anticancer immunity in the form of adaptive immune response. A low lymphocyte 
count might underlie an insufficient host immune  response48 due to destruction of lymphocytes by cancer 
 cells49. Consequently, the risk of cancer development and progression might increase in immunocompromised, 
lymphopenia  population48.
Given the retrospective nature of present study, there is a possibility of bias in patient selection and the 
results cannot be readily extrapolated to the general population. More data are needed to set the optimal cut-off 
values of SIMs that can be applied in clinical situations. In the future, a multicenter, prospective cohort study 
should be warranted for incorporating SIMs into a practical staging tool for OSCC. Another limitation is that 
our cohort included only patients who had undergone primary surgery-based treatment for OSCC. Patients who 
had received primary radiotherapy and/or chemotherapy were not included. Although there is no noticeable 
difference between the cut-off values according to the treatment modalities for OSCC, discreet approaches are 
required to interpret the findings of this study.
conclusion
A precise prediction of survival before curative surgery in OSCC is still challenging. In the framework of AJCC 
8th edition, the present study demonstrated that elevated NLR or PLR can be another preoperative clue to iden-
tify the patients who are in risk of shorter survival and higher recurrence. When pathologic data was included 
in multivariate analysis, elevated NLR and pN were independent predictors for poor OS and DFS, and PNI for 
worse OS. Although SIM need to be further validated, NLR is suggested to be of value in predicting survival 
outcomes during preoperative and postoperative assessment.
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